Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
Acta Pharmaceutica Sinica B
; (6): 1315-1328, 2021.
Article
in En
| WPRIM
| ID: wpr-881201
Responsible library:
WPRO
ABSTRACT
Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia (CML). Chemical degradation of Bcr-Abl
Full text:
1
Database:
WPRIM
Language:
En
Journal:
Acta Pharmaceutica Sinica B
Year:
2021
Document type:
Article